The chemistry behind the study rests on the Claisen-Schmidt condensation, a base-catalyzed reaction that joins an aromatic aldehyde with a ketone-bearing precursor to form conjugated enone linkages. Using this approach, the researchers assembled derivatives labeled 2 through 5, each carrying the benzenesulfonamide scaffold decorated with different heterocyclic appendages, including pyrazole rings fused or hybridized with pyrrolidine and thiophene units. The sulfonamide group itself has a storied history in medicine, having anchored the first generation of synthetic antibiotics in the 1930s, and it remains a versatile pharmacophore because its polar chemistry allows it to form hydrogen bonds with biological targets. By varying the heterocyclic partners attached to this core, the team could probe how subtle structural changes alter biological activity, a strategy known as structure-activity relationship exploration.

The larvicidal half of the study targeted Wohlfahrtia magnifica, the spotted flesh fly, whose larvae are obligate parasites that invade the living tissue of warm-blooded animals and cause a devastating condition known as traumatic myiasis. The disease inflicts severe losses in livestock and occasionally affects humans, and control options are narrowing as conventional insecticides lose efficacy and face regulatory restrictions. When the researchers exposed W. magnifica larvae to the compounds at a concentration of 25 milligrams per gram, the thienyl-pyrazole-hybridized derivative 5 emerged as the clear winner, driving cumulative mortality to approximately 92 percent by the fourth day of treatment. The other derivatives showed weaker effects, underscoring how the thiophene-pyrazole combination appears to be the key structural feature for insecticidal potency in this series.

What makes the study particularly compelling is the microscopic evidence of how the winning compound kills. Histopathological examination of treated larvae revealed extensive breakdown of the cuticle, the tough outer armor that insects depend on for protection and water balance. Beneath the surface, the muscle architecture collapsed, with myofibrils, the contractile fibers of larval muscle, fragmenting into disorganized debris. The mitochondria, the organelles that power cellular metabolism, swelled severely, a hallmark of energy failure and irreversible cellular stress. Perhaps most striking was the fate of the collagen-like extracellular matrix that supports larval tissues: quantitative assessment showed its abundance plummeting from roughly 80 percent in untreated specimens to below 15 percent after treatment, indicating a progressive disintegration of the structural scaffolding that holds the insect’s body together.

To determine whether the dying cells were undergoing programmed cell death, the team turned to acridine orange, a fluorescent dye that binds nucleic acids and reveals nuclear morphology under ultraviolet light. Staining of treated larvae showed condensation and fragmentation of nuclei in a treatment-dependent pattern, the classic cytological signature of apoptosis. This finding suggests that compound 5 does not simply poison larvae indiscriminately but triggers an organized self-destruction program within their cells, a mechanism that could be exploited to design more targeted and environmentally selective pest control agents in the future.

The antibacterial arm of the study focused on a different threat: multidrug-resistant Gram-negative pathogens. Here the ranking flipped. The pyrrolidine-pyrazole hybrid, compound 2, displayed selective and dose-dependent inhibition of Klebsiella pneumoniae, producing inhibition zones between 15 and 28 millimeters with a minimum inhibitory concentration of 10 milligrams per milliliter, and also curbed Escherichia coli with zones of 9 to 16 millimeters and an MIC of 25 milligrams per milliliter. Notably, the compound showed no activity against Staphylococcus aureus, a Gram-positive species, meaning its spectrum is confined to the outer-membrane-bearing bacteria that are hardest to attack with existing drugs. Klebsiella pneumoniae in particular has become one of the world’s most alarming reservoirs of resistance genes, capable of transferring drug tolerance to other species, so any new chemical scaffold with activity against it attracts immediate attention.

Scanning electron microscopy provided visual confirmation of the antibacterial mechanism at the cellular level. Treated bacterial cells exhibited rupture of the cell envelope and wholesale structural collapse, images consistent with a compound that damages the membrane and wall architecture rather than merely slowing growth. To pin down the molecular target, the researchers ran in vitro enzyme assays against two essential bacterial enzymes: DNA gyrase B and topoisomerase IV. These enzymes belong to the type II topoisomerase family and are responsible for managing the topological stress of DNA replication and transcription; they are the targets of fluoroquinolone antibiotics, against which resistance has spread widely. Compound 2 inhibited E. coli DNA gyrase B with an IC50 of 3.188 micromolar and topoisomerase IV with an IC50 of 14.288 micromolar, demonstrating genuine enzymatic inhibition rather than nonspecific toxicity.

Computational modeling then connected the biochemical data to atomic-scale structure. Molecular docking simulations placed compound 2 firmly within the ATP-binding cavities of both enzymes, yielding docking scores of minus 10.88 kilocalories per mole for DNA gyrase B and minus 9.98 kilocalories per mole for topoisomerase IV. Scores in this range indicate energetically favorable binding poses, and the fact that the compound engages both members of the topoisomerase family is significant because dual targeting makes it harder for bacteria to develop resistance through a single mutation. The docking results align with the enzyme assays, giving the inhibition data a plausible structural explanation and providing a template for future medicinal chemistry optimization.

Before any compound can move toward drug development, it must pass a gauntlet of predicted properties collectively known as ADMET profiling, covering absorption, distribution, metabolism, excretion, and toxicity. In silico analysis of the derivatives indicated good oral bioavailability, with a predicted human intestinal absorption rate of 94.87 percent for the lead compound, alongside a favorable drug-likeness profile and an acceptable safety window with respect to the hERG potassium channel, a common early warning screen for cardiac toxicity risk. These computational predictions do not replace laboratory pharmacokinetic testing, but they suggest that the scaffold is worth advancing rather than fundamentally flawed in its drug-like character.

The study’s dual findings, a potent larvicidal compound and a multi-target antibacterial lead emerging from the same synthetic series, illustrate the value of systematic heterocycle design around a proven pharmacophore. Compound 5 now stands as a candidate for further development against myiasis-causing flies, while compound 2 offers a starting point for optimizing inhibitors of bacterial DNA gyrase and topoisomerase IV at a time when Gram-negative resistance continues to erode the clinical utility of older antibiotic classes. The authors, led by Ahmed Abdou O. Abeed of Assiut University and Mustafa A. Fawzy of Taif University, acknowledge funding from Taif University’s Deanship of Graduate Studies and Scientific Research. As with all early-stage discovery work, the path from laboratory potency to practical insecticide or antibiotic is long, requiring toxicity studies in animal models, formulation development, and resistance selection experiments, but the combination of histological, ultrastructural, biochemical, and computational evidence assembled here gives both lead compounds a well-documented foundation for the next phase of evaluation.

Subject of Research: Synthesis and dual larvicidal and antibacterial evaluation of novel benzenesulfonamide derivatives

Article Title: Novel benzenesulfonamide derivatives as larvicidal and antibacterial agents: insights from histopathological studies, molecular docking, and ADMET profiling

Article References: Abeed, A. A. O., Fawzy, M. A., Abd El-Aziz, F. E.-Z. A., Alsharif, H., Afifi, T. H., Shikhoun, M. E. H., Ahmed, H. A., Nossier, E. S., & Kishk, F. N. M. (2026). Novel benzenesulfonamide derivatives as larvicidal and antibacterial agents: insights from histopathological studies, molecular docking, and ADMET profiling. 3 Biotech, 16(10), Article 450. https://doi.org/10.1007/s13205-026-05060-y

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05060-y

Keywords: benzenesulfonamide, larvicidal agents, Wohlfahrtia magnifica, antibacterial activity, DNA gyrase B, topoisomerase IV, Klebsiella pneumoniae, Escherichia coli, molecular docking, ADMET profiling, histopathology, antimicrobial resistance

The motivation behind the work lies in the arithmetic of the resistance crisis. In 2021, an estimated 4.71 million deaths worldwide were associated with bacterial antimicrobial resistance, including 1.14 million deaths directly attributable to it. Conventional antibiotics typically disable a single bacterial target, which means a single mutation can confer resistance. Newer strategies therefore seek agents that attack bacteria through several mechanisms at once, making it far harder for pathogens to survive. Antimicrobial peptides, the cationic membrane-attack molecules of the innate immune system, embody this philosophy, but their clinical use has been hampered by susceptibility to proteolysis, poor pharmacokinetics, and toxicity. Peptidomimetics, small molecules that mimic the architecture of these peptides, promise to retain their killing power while shedding their liabilities.

Clofoctol offered an unusually attractive starting point. Unlike generic hydrophobic scaffolds, it came with a documented history in humans: established pharmacokinetic behavior, pulmonary concentrations well above the levels needed to inhibit bacteria, and known effects on bacterial energy metabolism, including lowered intracellular ATP and disrupted membrane permeability. Its weaknesses were equally clear. It was essentially inactive against Gram-negative bacteria, poorly soluble in water, and potentially cytotoxic. Its precise molecular target had never been identified. Previous attempts to revive the drug had focused on reformulation and combination therapy, such as loading it into PLGA nanoparticles for lung delivery or pairing it with colistin against resistant Gram-negative pathogens. No one had yet redesigned the molecule itself.

The chemistry team, led by Jiayong Liu and colleagues, focused modifications on the phenolic hydroxyl group of clofoctol’s biphenyl scaffold, which defines the molecule’s hydrophobic domain. Through a modular synthetic route, they installed a library of cationic substituents, diethylamine groups, guanidinium groups, and chains of the amino acid arginine, connected by spacers of varying length. Each analogue was tested against a panel of Gram-positive and Gram-negative strains, including MRSA, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, with minimum inhibitory concentrations measured by standardized broth microdilution and hemolysis assessed against rabbit red blood cells.

The structure–activity relationships that emerged were instructive. Simple alkyl appendages abolished activity entirely, confirming that positive charge is essential for electrostatic engagement with negatively charged bacterial membranes. Spacer length proved critical: a four-carbon linker balanced potency and selectivity, while longer or shorter chains degraded one or both. Among the cationic groups, arginine emerged as the star. Tri-arginine substitution with a C-terminal methyl ester produced compound 30, which inhibited Gram-positive bacteria at just 0.39 micrograms per milliliter, a fourfold improvement over clofoctol on a weight basis, and brought E. coli activity from greater than 50 micrograms per milliliter down to 1.56. Its hemolytic activity was undetectable even at 200 micrograms per milliliter, yielding a selectivity index exceeding 512.

Compound 30 also tackled some of the most feared hospital pathogens. It retained potency against carbapenem-resistant Enterobacterales strains of E. coli and Klebsiella at concentrations of 1.56 to 3.125 micrograms per milliliter, conditions under which amoxicillin was essentially inert. Quantitative analysis of the SAR data reinforced a key design principle: calculated lipophilicity correlated negatively with both potency and selectivity, meaning that simply making the molecule greasier did not help. Success required a calibrated balance of charge and hydrophobicity, precisely the balance that tri-arginine esterification achieved. The modification also cured clofoctol’s solubility problem; compound 30 remained clear in water at 100 milligrams per milliliter, a concentration at which the parent drug was visibly insoluble even at one-tenth that level.

Time-kill experiments revealed remarkably fast bactericidal kinetics. At eight times the MIC, compound 30 completely eradicated both S. aureus and E. coli cultures within one hour, whereas vancomycin needed far longer and amoxicillin required a full day. Serial passage experiments underscored another advantage: over 21 transfers, the compound’s MIC never shifted, while norfloxacin resistance in S. aureus rose 256-fold by day 11 and amoxicillin resistance in E. coli climbed 16-fold by day 16. The compound also throttled biofilms, reducing S. aureus biofilm formation by more than 93 percent at twice the MIC and dismantling 83 percent of established E. coli biofilms at four times the MIC. Activity remained stable under physiological salt concentrations, a hurdle that defeats many cationic antimicrobials.

Mechanistic probing pointed to membrane disruption as the best-supported component of the compound’s action. SYTOX Green uptake, NPN permeability assays, and Live/Dead staining all showed concentration-dependent compromise of bacterial membrane integrity, and compound 30 displaced a fluorescent probe from lipopolysaccharide, the anchor of the Gram-negative outer membrane, by more than 80 percent at twice the MIC. Additional effects layered on top of this primary mechanism. In a purified-enzyme assay, compound 30 inhibited E. coli topoisomerase IV-mediated DNA decatenation by 96 percent at twice the MIC, and molecular docking into the ATP-binding pocket of the ParE subunit yielded a plausible binding pose at −10.2 kilocalories per mole, although the authors caution that intracellular target engagement has not yet been demonstrated. Treatment also depleted intracellular ATP and triggered reactive oxygen species accumulation; adding the ROS scavenger N-acetylcysteine raised the compound’s MIC four- to eightfold, supporting a functional contribution of oxidative stress to bacterial killing.

Transcriptome sequencing of E. coli after two hours of exposure identified 129 differentially expressed genes among 4,491 analyzed, with enrichment in the tricarboxylic acid cycle, methionine biosynthesis, and fatty acid catabolism, a pattern consistent with the observed energy and redox disturbances. The authors are careful to frame these as treatment-associated cellular responses rather than proof of direct targets, and the hierarchy among membrane damage, metabolic collapse, oxidative stress, and topoisomerase inhibition remains to be causally disentangled. What is clear is that the compound engages bacteria on multiple fronts, which plausibly explains both its rapid killing and its stubborn refusal to select for resistance under laboratory conditions.

The in vivo results, though early-stage, provide the most compelling evidence yet that the strategy can translate. In a murine keratitis model, topical 0.5 percent compound 30 reduced corneal S. aureus burden by 4.65 log units, statistically indistinguishable from 5 percent vancomycin, and cut P. aeruginosa burden by 3.81 log units, comparable to 0.3 percent gatifloxacin. Ocular safety testing with fluorescein staining showed no corneal epithelial damage even at three times the therapeutic dose. The authors emphasize that considerable work remains before clinical development: pharmacokinetics, corneal penetration, metabolic stability, long-term repeat-dose safety, broader panels of clinical isolates, and the precise causal mechanisms all require further study. Still, the study demonstrates a principle with wide implications. Rather than designing peptide mimics from scratch or hunting for entirely new scaffolds, medicinal chemists can take clinically validated drugs, install the cationic amphiphilic features that make antimicrobial peptides lethal, and produce candidates that are soluble, selective, fast-acting, and resistance-resistant. As the pipeline of conventional antibiotics continues to run dry, that recipe may prove one of the most practical paths forward.

Subject of Research: Development of clofoctol-derived cationic amphiphilic peptidomimetics as multi-mechanism broad-spectrum antibacterial agents

Article Title: Clofoctol-derived amphiphilic peptidomimetics exhibit broadened antimicrobial activity via multiple contributing mechanisms

Article References: Liu, J., Lin, J.-H., Wang, W., Li, H., Zheng, Y., Zhang, Y., Chen, M., Zhong, R., Xing, C., Dang, Y., Chang, H., Liu, S., & Lin, S. (2026). Clofoctol-derived amphiphilic peptidomimetics exhibit broadened antimicrobial activity via multiple contributing mechanisms. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.09.007

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.09.007

Keywords: antimicrobial resistance, clofoctol, peptidomimetics, antibiotics, membrane disruption, MRSA, Gram-negative bacteria, biofilms, keratitis, drug discovery, topoisomerase IV, reactive oxygen species